IDCRC Newsletter: July 2024IDCRC Investigator Profile: Mary Healy, MDDr. Healy is an associate professor of pediatrics, in the Section of Infectious Diseases, at Baylor College of Medicine. In addition to her clinical practice, Dr. Healy has been involved in clinical research for over two decades. Her research interests focus on preventing infections through immunization for all age groups, with a special interest in maternal immunization, particularly in evaluating immunization strategies to prevent severe pertussis in infants. She has also served as a co-investigator for the Baylor VTEU and has been intimately involved with IDCRC/VTEU projects where Baylor serves as a clinical site, including as national co-chair of Stage 2 (adolescent) Mpox clinical trial Dr. Healy was recently announced as the IDCRC Leadership Group (LG) Clinical Operations Unit (COU) co-director. Read the full announcement of her recent appointment here. VTEUs launch Phase 1 Trial of Nasal COVID-19 Vaccine Congratulations to Baylor College of Medicine, The Hope Clinic of Emory University and New York University, Long Island, who recently launched a Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protections against emerging variants of SARS-CoV-2. The trial aims to enroll 60 adult participants, ages 18-64 years old, who previously received at least three prior doses of an FDA-approved or -authorized mRNA COVID-19 vaccine. Hana M. El Sahly, MD, at the Baylor College of Medicine Vaccine Research Center, is leading the study, which is the first NIAID clinical trial to be conducted as part of the U.S. Department of Health and Human Services (HHS) Project NextGen. Dr. El Sahly previously served as one of the protocol chairs for the IDCRC-led initiative to develop an initial protocol for conducting Phase ½ study of Intranasal SARS-COV-2 vaccines, prior to the NextGen project being initiated through NIAID and BARDA. IDCRC study evaluating the safety of investigational monoclonal antibody to treat enterovirus D68 (EV-D68) enrolls first participant The IDCRC recently began enrolling a first-in-human clinical trial to evaluate the safety of an experimental monoclonal antibody against enterovirus D68 (EV-D68), which can cause severe respiratory disease and neurological diseases such as acute flaccid myelitis (AFM) — similar to polio. The Phase 1 placebo-controlled double-blinded study, led by Principal Investigator C. Buddy Creech, MD, MPH, at Vanderbilt University Medical Center, enrolled their first participant at the end of June. The trial will be conducted with a total of 36 healthy volunteers, ages 18 to 49. The University of Maryland, Baltimore, led by Elizabeth Adrianne Hammershaimb, MD, will also begin enrolling participants as a second site soon. Clinical Infectious Diseases SupplementThe IDCRC Collaborations and Publications Committee is organizing a Clinical Infectious Diseases Supplement, highlighting the accomplishments and future goals of the IDCRC. We are working on forming the writing team. All roles are invited to contribute. VTEU staff and investigators are required to obtain approval from their VTEU PI to contribute effort to this manuscript. If you would like to join this team, please complete the survey at the button below, and select your area of interest. Responses are due by August 2, 2024. PublicationsDid you know that we have a resource guide to help you with publications? Check out this one-page overview for quick reminders on the following and much more!
Congratulations CornerWe are thrilled to celebrate our colleague, Britta Flach, LOU Operations Manager, on the arrival of her daughter, Isabella Taylor Flach, born on June 27, 2024. Please join us in welcoming Isabella to the IDCRC family! Share your news with the IDCRC We want to hear from you! Do you have news to share, personal or professional? Do you know someone in the IDCRC who deserves a spotlight? Send us an email at idcrc@emory.edu to be featured in an upcoming IDCRC newsletter! 2025 Annual MeetingSave the date! Next year’s annual meeting will take place from April 30-May 1, 2025. We look forward to seeing you there. Date: April 30-May 1, 2025 Stay tuned for more information! Click below to learn more about this annual event, and check out our 2024 recap story for insight into what to expect for next year's meeting. NewsMonica Farley, MD, appointed to the National Foundation for Infectious Diseases leadership team On July 9, the National Foundation for Infectious Diseases (NFID) announced the 2024-2025 NFID Board of Directors and updated slate of officers and named Monica Farley, MD, (Emory University) as their President-Elect. The National Foundation for Infectious Diseases (NFID) is a non-profit 501(c)(3) organization dedicated to educating and engaging the public, communities, and healthcare professionals about infectious diseases across the lifespan. Congratulations, Dr. Farley! Angelica Kottkamp, MD, recognized by The abstract entitled "MVA-BN Induces a Low Avidity, Non-Durable Humoral Response Against Mpox Virus", submitted by Angelica Cifuentes Kottkamp, MD, (NYU Grossman School of Medicine), has been selected by the 2024 IDWeek Program Committee as one of the four best-accepted abstracts overall. Dr. Kottkamp was invited to present this work in a major named lecture session, the Smadel Lecture. In addition, for her outstanding scientific research, the Committee selected Dr. Kottkamp for a $2,500 travel award meant to help defray the expenses of traveling to this year's ID Week. Congratulations to Angelica and her collaborators in the NYU Vaccine Center research clinic, the research laboratory, biostatistics, and the NYC Department of Health & Mental Hygiene! Job PostingsInfectious Diseases Research Job Openings
Visit the IDSA Career Center to browse other ID/HIV Medicine job postings. Funding OpportunitiesNIH Funding Opportunities Specific to COVID-19 Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) (R41/R42 Clinical Trial Not
Allowed) – Due 30 days prior (LOI); Thursday, September 5, 2024; January 5, 2025; April 5, 2025; 2025; 2026; 2027 (Full application) NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) – Due 30 days prior; September 13, 2024; January 16, 2025; May 13, 2025; September 15, 2025; January 13, 2026; May 13, 2026; September 14, 2026; Janaury 13, 2027 NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) – Due 30 days prior (LOI); November 11, 2024; October 10, 2025 (Full application) Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine – Due January 8, 2025
Notice of Special Interest (NOSI): Competitive Revision Supplements to Existing T32 Programs to Include Institutional Research Training in Data Science for Infectious and Immune Mediated Diseases – Due January 8, 2025 Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission – Due March 13, 2025; 2026 Notice of Special Interest (NOSI): Complement in Fundamental Immunology – Due January 8, 2026 Notice of Special
Interest (NOSI): Research to Stimulate Development of Diagnostics, Therapeutics, and Vaccines for Herpes Simplex Virus (HSV) – Due April 6, 2027 IDCRC StudiesActive Studies
Fully Enrolled Studies
IDCRC Concept Quick StatsICP Status
EWG Assignment
ECP Status
Communication ResourcesPlease submit IDCRC news to idcrc@emory.edu for inclusion in the monthly newsletter and IDCRC.org. |